Hyku names Kleem Chaudhary CEO
Plus: Jones hired as CBO at MOMA, and updates from Metrion, OPPI, 4BIO and Quotient
Hyku Biosciences Inc. named Kleem Chaudhary as president and CEO, succeeding co-founder and acting CEO Milind Deshpande, who will become an adviser to the company. Chaudhary, who also joins Hyku’s board, was chief operating and business officer at Redona Therapeutics Inc., before which he was CBO at Checkmate Pharmaceuticals Inc. Hyku is expanding the druggable proteome with a library of small molecules targeting histidine, tyrosine and lysine residues, and a cell-based screening method that enables the company to quickly determine to which proteins they bind.
Jullian Jones became CBO at MOMA Therapeutics Inc., which is developing therapies from its KnowledgeBase drug discovery platform. Jones was CBO at Monte Rosa Therapeutics Inc. (NASDAQ:GLUE)...